Biomedical subjects

N T Buu

Publications and source records attributed to N T Buu.

At least 55 records · Page 3Linked to original sources

PubMed1986

Handling of dopamine and dopamine sulfate by isolated perfused rat kidney.

The possible contribution of circulating dopamine sulfate to urinary free dopamine and the synthesis of norepinephrine by the renal nerves were examined in the isolated perfused rat kidney. Perfusion of the kidney with dopamine sulfate did not yield significant amounts of free dopamine indicating that, unlike L-dopa, dopamine sulfate is not a good source of urinary free dopamine. The excretion of dopamine sulfate was slower than or comparable with that of free dopamine, suggesting that sulfoconjugation is not a mechanism to facilitate the excretion of free dopamine. Unlike free dopamine, dopamine sulfate was not metabolized by renal catechol-O-methyltransferase or monoamine oxidase. Perfusion of L-dopa and free dopamine led to the generation of norepinephrine in the kidney. This synthesis was abolished when the kidney was denervated, suggesting that the renal nerves were the main sites of the norepinephrine synthesis. Both norepinephrine and dopamine were rapidly metabolized by catechol-O-methyltransferase and monoamine oxidase, but renal phenolsulfotransferase appeared to have no action on the catecholamines.

3,4-Dihydroxyphenylacetic Acid↗

PubMed1986

Metabolism and storage of catecholamines in rats with pheochromocytoma implants.

New England Deaconess Hospital rats implanted with a pheochromocytoma P259 became hypertensive and showed high concentrations of plasma dopamine (42.0 +/- 14.6 ng/ml) and norepinephrine (45.7 +/- 8.4 ng/ml). However, the norepinephrine content of several peripheral tissues of these rats did not differ from those of the New England Deaconess Hospital control rats, and their dopamine content, although slightly higher, was much lower than would have been expected from the plasma dopamine levels. Methylation by catechol-O-methyltransferase did not appear to play a major role in the inactivation of tissue catecholamines since there were no noticeable increases of normetanephrine or 3-methoxytyramine in the tissues of the rats with pheochromocytoma. There was also no increase in conjugated dopamine, in either the sulfate or glucuronide form, in the plasma or tissue of the hypertensive rats, although injection of L-dopa induced a large increase in dopamine sulfate in the plasma and urine of these rats. This finding indicated that, although their sulfoconjugation mechanism was intact and not affected by the pheochromocytoma, it did not participate in the metabolism of dopamine released by the tumor into the blood. On the other hand, plasma and urine of tumor-bearing rats exhibited abnormally high concentrations of homovanillic acid, the main metabolite of dopamine resulting from monoamine oxidase action. In contrast to the control rats, intravenous infusion of free dopamine in rats with pheochromocytoma had no effect on plasma free dopamine levels but increased homovanillic acid levels considerably. The present data underline the important role of monoamine oxidase in the removal of excessive quantities of catecholamines released by the tumor in New England Deaconess Hospital rats with the pheochromocytoma implant.

Adrenal Gland Neoplasms↗

PubMed1986

Involvement of the adrenal glands in the action of the atrial natriuretic factor.

Adrenalectomized, medullectomized and sham operated rats were treated with either a chronic infusion or a bolus injection of the synthetic atrial natriuretic factor (ANF). ANF did not enhance natriuresis and diuresis in sham operated conscious animals during chronic infusion, but it had a potent action when injected as a bolus into anesthetized rats. The absence of the whole adrenal glands, but not adrenal medulla profoundly modified the renal response to ANF: a) following chronic administration of ANF, the baseline natriuresis paradoxically decreased in adrenalectomized rats, and b) in response to a bolus injection of ANF the natriuretic and diuretic actions of the peptide were attenuated in these animals. The medullectomy-induced decreased natriuresis and dopamine excretion were corrected by ANF infusion. Furthermore, ANF suppressed the compensatory increase of norepinephrine excretion secondary to adrenalectomy. The data suggest that the presence of the adrenal cortex is necessary for the natriuretic and diuretic actions of ANF. The decrease in urinary DA excretion may reflect diminished dopaminergic activity and contribute to the post-medullectomy antinatriuresis, a phenomenon which can be corrected by ANF infusion. ANF may also have a depressing activity on the increased sympathetic tone.

Adrenal Glands↗

PubMed1986

The blood pressure decrease-induced sympathetic discharge following atrial natriuretic factor administration may offset its natriuretic action.

Conscious SHR and WKY rats were infused during 7 days with ANF (Arg 101-Tyr 126), 100 ng/hr/rat, by means of miniosmotic pumps and their basal blood pressure (BP), changes in sodium excretion and urinary catecholamines compared with those at the last day of the infusion. The SHR initial BP of 181 +/- 3 mmHg gradually declined to 137 +/- 5 mmHg. No significant change in blood pressure was observed in the ANF-infused WKY group. However, WKY rats exhibited an increased sodium excretion and urinary dopamine/norepinephrine ratio when compared to sham-infused rats. No such differences were observed in SHR. It is suggested that an ANF-induced withdrawal of the renal sympathetic tone permits the manifestation of its natriuretic action in WKY rats. When, however, a BP decrease predominates, as in SHR, this decrease results in a reflex sympathetic discharge with a renal sympathetic activity over-riding the ANF induced natriuresis seen in WKY rats. Secondary sympathetic responses to the ANF-induced BP decrease have to be thus taken into account when a dissociation between the hypotensive and natriuretic action of ANF is observed in vivo.

Animals↗

PubMed1986

Episodic dopamine discharge in paroxysmal hypertension. Page's syndrome revisited.

Dopamine concentration, a marker of the sympathetic discharge additional to norepinephrine and epinephrine levels, was determined in 31 patients. These patients, mostly women, had essential hypertension and hypertensive episodes that mimicked pheochromocytoma, except that the patients were rather plethoric (instead of pale) and often had associated nausea, epigastric discomfort, and polyuria. During and after hypertensive paroxysms, plasma free norepinephrine and epinephrine levels did not increase, but we found a mean eightfold and 16-fold increase of free and sulfated plasma dopamine levels, respectively, and similar although less marked dopamine level increases in the urine collected following the paroxysm. The hypertensive paroxysms, spontaneous or precipitated by stimulation of the autonomic nervous system, were similar to those described by Page as simulating diencephalic stimulation. Dopamine level may be a marker of the sympathetic discharge, undetected by measurements of free norepinephrine level, and may explain some clinical features of Page's syndrome.

Adrenal Gland Neoplasms↗

PubMed1986

Role of sulfate conjugation of catecholamines in blood pressure regulation.

Catecholamine sulfates were found to be inactive at vascular receptor sites. Only at one nonvascular receptor site important for blood pressure (BP) regulation was dopamine-3-O-sulfate found to be an inhibitory modulator of the adrenocortical secretion of aldosterone in vitro. However, sulfation of catecholamines (CA) does play an important role in BP regulation, as shown by the following observations: Sulfoconjugated CA with a long half-life are sometimes better markers of CA release than free CA, which have short half-lives. This is particularly true of dopamine (DA) sulfate because free DA, being rapidly sulfoconjugated, is usually undetectable. This led to the recognition of a previously unsuspected role of DA in paroxysmal hypertension and orthostatic hypotension. Measurements of CA sulfates reveal potentially important storage functions for sulfoconjugation that can rapidly inactivate excessive circulating free CA and so mitigate their cardiovascular impact while building up a pool of conjugated CA. The possibility that free CA can be generated from this pool through deconjugation whenever a need for them arises should be further investigated. Reproducible individual differences in the velocity of the sulfoconjugation of infused free CA can be detected, which suggests a genetic control of certain components of the sulfoconjugating process. These differences in sulfoconjugation probably modulate the cardiovascular action of CA and of some drugs with similar structure that also undergo sulfoconjugation.

Adrenal Cortex↗

PubMed1985

Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens.

We demonstrate that injections of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP), 1-methyl-4-phenyl-pyridinium ion (MPP+) and Paraquat (PQ+) produce in Rana Pipiens different behavioral, biochemical and skin pigmentation changes. MPTP causes in frogs the main symptoms of Parkinsonism (rigidity, akinesia and tremor) and it darkens the skin of animals. It also decreases brain and, less so, adrenal medulla dopamine. These effects are blocked by Pargyline. MPP+ causes the same symptoms but more rapidly. In contrast, skin pigmentation is clearly lightened. Brain and particularly adrenal dopamine reserves are nearly abolished. Pargyline increases these effects. Paraquat, in a cumulative fashion, eventually causes the same behavioral changes and a slight increase in pigmentation. It initially produces an increase in brain and adrenal dopamine concentrations, but later a significant dopamine concentration decrease. Pargyline potentiates these long term effects, blocks the dopamine increase, but reverses the PQ+ effect upon melanin, producing the same depigmentation as MPP+ alone.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

PubMed1985

New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

We report the development of two animal models in amphibians (frogs and salamanders) in whom 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces the behavioral (neurological) and biochemical equivalents of the human disease and, in addition, a measurable modification in at least one form of pigment-bearing cell from the neural crest, the skin melanocyte. We propose that this new approach can become an inexpensive, easily quantifiable model for the study of the effect of MPTP on the central and peripheral nervous systems. We also demonstrate that the toxic effect of MPTP can be completely abolished in vivo by treatment with a monoamine oxidase inhibitor and potentiated by an inhibitor of catechol-O-methyltransferase. MPTP is catabolised by oxidation into toxic metabolites, but 1-methyl-4-phenylpyridinium ion (MPP+), the proposed end-metabolite, is even more toxic than MPTP in this model, possibly through a different mechanism.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

PubMed1985

In vivo release of adrenal catecholamines in rats by fusaric acid.

We studied the effect of fusaric acid, an inhibitor of dopamine beta-hydroxylase (D beta H), on plasma and peripheral tissue catecholamine (CA) content and on urinary excretion of CA in the rat. We found that fusaric acid treatment resulted in a rapid decline of adrenal epinephrine (E) and norepinephrine (NE) and an increase of adrenal dopamine (DA); the kidney and heart NE and DA contents were affected in a pattern similar to that of the adrenals. In contrast, the E concentrations in the kidneys and heart were markedly elevated after a single intraperitoneal dose of fusaric acid (100 mg/kg); the maximum response was observed at 60 min, when kidney E increased from 9.3 +/- 4.4 to 101 +/- 24 pmol/g tissue and heart E in both atrium and ventricle rose from 92 +/- 8 to 607 +/- 85 pmol/g tissue and from 70 +/- 4 to 632 +/- 50 pmol/g tissue, respectively. In addition, a large increase of CA (predominantly of E) was found in the plasma of treated rats, where E, NE and DA were 27, 6.6 and 2.7 times higher than control values, respectively. The excretions of urinary E and NE were also significantly elevated during treatment. Fusaric acid-treated bilaterally adrenalectomized rats did not exhibit any increase in plasma, heart and kidney E concentrations. The results suggest that fusaric acid stimulates adrenal CA release in vivo, resulting in large increases of the main adrenal CA, E in peripheral tissues, plasma and urine. The decline in the adrenal E content is thus not only due to its decreased synthesis but also increased release.

Adrenal Glands↗

PubMed1985

CSF sulfoconjugated catecholamines in man: their relationship with plasma catecholamines.

Simultaneous plasma and cerebrospinal free and sulfoconjugated norepinephrine, epinephrine, dopamine and homovanillic acid determinations in 38 patients with various neurological disorders have shown consistently lower concentrations of dopamine sulfate, norepinephrine sulfate, and epinephrine sulfate in the cerebrospinal fluid than in plasma. An approximately three fold increase of plasma dopamine sulfate concentrations following banana ingestion did not result in increased dopamine sulfate concentrations in cerebrospinal fluid. There were positive correlations between plasma and cerebrospinal fluid concentrations of free norepinephrine and epinephrine as well as norepinephrine sulfate, dopamine sulfate and free homovanillic acid. Cerebrospinal fluid and plasma are apparently separated by the blood-brain barrier impermeable to catecholamine sulfates from the blood. Some other data and the observed positive correlation between cerebrospinal fluid and plasma dopamine and norepinephrine sulfates suggests however that catecholamine sulfates may pass from cerebrospinal fluid to the blood and reflect events in the brain.

Adolescent↗

PubMed1985

Effect of metoclopramide on plasma catecholamine release in essential hypertension.

The catecholamine (CA)-releasing action of metoclopramide (MCP) observed in patients with pheochromocytoma was tested in 20 subjects with essential hypertension and compared with the same effect of glucagon in 10 of them. We found that even in the absence of pheochromocytoma, MCP is a CA-releasing substance, moderately increasing systolic blood pressure and pulse rate. The release of CA is reflected by an increase in concentrations of free norepinephrine and total (free plus sulfated) epinephrine 3 minutes and of total dopamine and norepinephrine 10 minutes after the MCP bolus dose, whereas glucagon had an effect on the release of free epinephrine. Regional catheterization before and after MCP dosing in one subject showed a considerable increase in adrenal epinephrine and norepinephrine concentrations 45 seconds after the MCP bolus dose. MCP has a free CA-releasing potency much like that of glucagon. Because the released free CA is readily sulfoconjugated, the effect on CA release can be more easily detected when conjugated CA is determined. MCP should thus be used with caution in pheochromocytoma as well as in other forms of hypertension.

Adult↗

PubMed1985

The platelet phenolsulfotransferase is not indispensable for the sulfoconjugation of plasma catecholamines.

To investigate the role of platelets, a proposed primary site of catecholamine sulfoconjugation, we determined plasma free and sulfoconjugated catecholamines and platelet phenolsulfotransferase activity in severe platelet defficiency states. We found that even in the presence of very low platelet counts, the plasma concentrations of sulfoconjugated catecholamines were within normal limits. Although the platelet phenolsulfotransferase activity expressed per number of platelets was normal there was a considerable decrease of the total platelet phenolsulfotransferase activity. This suggests that the platelet phenolsulfotransferase is not indispensable for the sulfoconjugation of catecholamines and this process can occur elsewhere. A preliminary finding of lower platelet phenolsulfotransferase activity in platelet deficiency states with reduced platelet generation (because of reduced megakaryocytes) than in those states with a decreased platelet survival, suggests that the phenolsulfotransferase is synthesised in the megakaryocytes and the platelets are only carriers of this enzyme.

Arylsulfotransferase↗

PubMed1985

Orthostatic hypotension: a posture-induced hyperdopaminergic state.

To explore the role of dopaminergic mechanisms in orthostatic hypotension we compared the postural responses of 20 such patients to those of a control group by radioenzymatic determination of free and sulfated catecholamines and related indices. Patients with orthostatic hypotension, unlike control subjects, experienced an increase in total plasma dopamine (DA) (free + sulfate) in response to upright posture (p less than 0.01). Of the 20 patients with orthostatic hypotension, 16 were normo- or hyperadrenergic with normal basal and posture-responsive or hyperresponsive plasma free and total norepinephrine (NE). The other 4 were hypoadrenergic with low basal and posture-unresponsive NE. Hypoadrenergic patients had, in the upright position, no increase in pulse rate and more severe hypotension, less diuresis and natriuresis, lower urinary free and total DA, lower total NE excretion, and higher plasma and urinary total DA:total NE ratio than normo- or hyperadrenergic patients or control subjects. Normo- or hyperadrenergic patients had higher PRA and plasma aldosterone in the upright position than hypoadrenergic patients or control subjects (all p less than 0.05). We suggest that an excessive increase in free DA occurs in response to upright posture, perhaps representing a compensatory reaction of the remaining autonomic nervous system to an excessive fall in blood pressure. The free dopamine may be biologically active but it is so rapidly sulfoconjugated that it can be detected only as DA sulfate. These findings, combined with reports of orthostatic hypotension precipitated by administration of dopaminomimetic drugs and relieved by administration of dopaminergic antagonists, are consistent with the interpretation that excessive DA release may perpetuate, by its vasodilating and natriuretic action, the orthostatic hypotension.

Adult↗

PubMed1985

Dopamine sulfoconjugation in the rat brain: regulation by monoamine oxidase.

An increase of free 3,4-dihydroxyphenylethylamine (DA, dopamine) in the rat brain such as is found following 3,4-dihydroxyphenylalanine (L-DOPA) administration or an intraventricular injection of free dopamine did not result in DA sulfate formation, despite the presence of phenolsulfotransferase activity in various regions of the brain and the high affinity of DA for this enzyme. However, when rats were pretreated with pargyline, a monoamine oxidase inhibitor, the same treatment with L-DOPA or free DA led to active synthesis of DA sulfate. The increase in DA sulfate was significantly correlated with the degree of monoamine oxidase inhibition and directly proportional to free DA concentrations in the hypothalamus (r = 0.86), striatum (r = 0.54), and brainstem (r = 0.89). The highest ratio of DA sulfate to free DA was found in the hypothalamus, suggesting that sulfoconjugation is most active in this region. Prior treatment of rats with 6-hydroxydopamine did not decrease DA sulfate concentrations, indicating that sulfoconjugation occurs most likely in extraneuronal tissues not destroyed by the neurotoxin. The results are compatible with the notion that phenolsulfotransferase may be highly compartmentalized and that inhibition of monoamine oxidase allows the newly generated free DA to become accessible to the sulfoconjugating enzyme, resulting in increase in DA sulfation.

3,4-Dihydroxyphenylacetic Acid↗

PubMed1985

Relationship between catechol-O-methyltransferase and phenolsulfotransferase in the metabolism of dopamine in the rat brain.

The relationship between phenolsulfotransferase (PST) and catechol-O-methyltransferase (COMT) in the metabolism of free 3,4-dihydroxyphenylethylamine (DA, dopamine) in the rat brain was studied. In rats not pretreated with a monoamine oxidase (MAO) inhibitor a huge increase of free DA in the brain, following an intraperitoneal injection of L-3,4-dihydroxyphenylalanine (L-DOPA) or an intraventricular injection of free DA, did not lead to any noticeable change in DA sulfate or 3-methoxytyramine (3-MT), which remained undetectable by the present HPLC method. However, in rats previously treated with the MAO inhibitors pargyline or tranylcypromine, the same L-DOPA or free DA treatment resulted in significant increases in both 3-MT and DA sulfate in the hypothalamus, brainstem, and striatum. This response of COMT and PST was not affected by prior treatment of the rats with 6-hydroxydopamine, which suggests that O-methylation and sulfoconjugation occur outside adrenergic neurons not destroyed by the neurotoxin. Inhibition of COMT activity did not lead to any increase in DA sulfate, which showed that despite their common mode of action (both enzymes react preferentially at the same hydroxyl group in the DA molecule), the two enzymes are not competitive. After MAO inhibition there were strong correlations between an increase in DA sulfate and 3-MT on the one hand, and between free DA and 3-MT on the other. Because 3-MT is a marker of central DA release, these data suggest that inhibition of MAO activity not only affects DA metabolism by this enzyme but also influences DA release in the rat brain.

Animals↗

PubMed1985

Effects of L-DOPA on the concentrations of free and sulfoconjugated catecholamines in plasma, cerebrospinal fluid, urine, and central and peripheral nervous system tissues of the rat.

The effects of subcutaneous injection of L-beta-3,4-dihydroxyphenylalamine (L-DOPA) on the concentrations of the catecholamines and catecholamine sulfates in the central and peripheral nervous systems of the rat were studied. The results showed that free 3,4-dihydroxyphenylethylamine (DA, dopamine) increased rapidly and markedly in the hypothalamus and striatum after L-DOPA but DA sulfate did not change. Increased concentrations of DA sulfate were detected in the CSF and in the plasma, where it reached a concentration of 130.8 +/- 12.8 ng/ml at 2 h, seven times the level of free DA (19.1 +/- 2.9 ng/ml). In the kidney the ratio of DA sulfate to free DA was reversed in favor of free DA. Urine samples of L-DOPA-treated rats showed a higher increase of free DA than DA sulfate, but free norepinephrine (NE) and NE sulfate remained unchanged. Concentrations of free DA and free NE in the adrenal glands of L-DOPA-treated rats showed no change. Adrenal DA sulfate and NE sulfate were not detectable in the control and L-DOPA-treated rats, suggesting that the adrenal glands lack the capacity to take up or store catecholamines and their sulfate counterparts from the plasma.

Adrenal Glands↗

PubMed1985

Peripheral dopamine synthesis and metabolism in spontaneously hypertensive rats.

We have studied several parameters of peripheral dopamine synthesis and metabolism in spontaneously hypertensive rats during the development of hypertension. Compared to Wistar-Kyoto rats, there was an increased dopamine content in 8-week-old spontaneously hypertensive rats in the adrenals (1.6 +/- 0.1 vs. 1.2 +/- 0.1 nmol/pair in Wistar-Kyoto rats) and kidneys (97 +/- 12 vs. 63 +/- 7 pmol/g tissue in Wistar-Kyoto rats), but the dopamine content in peripheral organs from normotensive 4-week-old spontaneously hypertensive rats did not differ from Wistar-Kyoto rats. In the heart, the dopamine increase was observed in 14-week-old spontaneously hypertensive rats (systolic blood pressure: spontaneously hypertensive rats, 189 +/- 9; Wistar-Kyoto rats, 106 +/- 2 mm Hg;) in both atrium (spontaneously hypertensive rats, 133 +/- 14; Wistar-Kyoto rats, 86 +/- 20 pmol/g tissue) and ventricle (spontaneously hypertensive rats, 41 +/- 6; Wistar-Kyoto rats, 23 +/- 5 pmol/g tissue). Urinary free dopamine and dihydroxyphenylacetic acid, but not norepinephrine or normetanephrine, in spontaneously hypertensive rats significantly increased between the ages of 7 and 11 weeks, reflecting the dopamine changes in tissue and suggesting a selective increase of the rate of dopamine synthesis and release.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenal Glands↗

PubMed1985

Circadian variations of free and sulfoconjugated catecholamines in normal subjects.

Normotensive recumbent subjects exhibit an early (11 p.m.) nocturnal increase in plasma dopamine, norepinephrine and epinephrine sulfates. In individual patients, this peak value is followed by a smaller nocturnal peak of catecholamine sulfates, while free catecholamine levels change in a direction opposite to catecholamine sulfates. This reciprocity of changes cannot however be demonstrated in the whole group. The origin of the nocturnal peaks of catecholamine sulfates is unknown. It may be due to a nocturnal decrease of the renal clearance of catecholamine sulfates, an increased generation of sulfates for reasons other than an increase in the free catecholamine substrate, or possibly a release of catecholamine sulfates from the brain.

Adult↗